Megestrol acetate in advanced breast carcinoma

Area of Science:

• Oncology
• Endocrinology

Background:

• Hormonal therapy represents the oldest treatment modality for advanced breast cancer.
• Historically, oophorectomy reduced endogenous hormone levels, but drug therapies now dominate.
• Current treatments include hormone secretion inhibitors and steroid activity blockers.

Purpose of the Study:

• To review the efficacy and side effect profile of hormonal therapies in advanced breast cancer.
• To assess the role of megestrol acetate in comparison to other hormonal agents.

Main Methods:

• Review of clinical trials involving hormonal manipulations for advanced breast cancer.
• Analysis of data from over 2,000 patients treated with megestrol acetate.
• Comparison of megestrol acetate efficacy with tamoxifen and other hormonal treatments in randomized trials.

Main Results:

• Hormonal therapies, including estrogens, androgens, and progestins, demonstrate a 20-40% overall response rate.
• Megestrol acetate achieved a 27% response rate in clinical trials.
• Efficacy of megestrol acetate was found comparable to tamoxifen and other hormonal treatments at a standard dose of 160 mg/day.

Conclusions:

• Megestrol acetate is an effective hormonal treatment for advanced breast cancer, with efficacy comparable to tamoxifen.
• Weight gain is the primary side effect associated with megestrol acetate at standard doses.
• Ongoing research is exploring higher doses of megestrol acetate for potentially increased response rates with acceptable toxicity.